window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : October 4, 2025

  • News
  • About Us
Contact Us

Chronic diseases

  • Central Nervous System,Chronic diseases,Drug Delivery & Formulation,European biotech,Pharmaceuticals and therapeutics

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    October 3, 2025
  • Biologics & Biosimilars,Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Levicept to present Phase 2 LEVI-04 data showing bone marrow lesion and pain reduction at ACR Convergence 2025

    Levicept Ltd will present new findings from its Phase 2 [...]

    October 2, 2025
  • Chronic diseases,Clinical Development,Clinical studies,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    Amorphical reports positive interim results from ongoing Crohn’s disease trial

    Amorphical, developer of nano-amorphous mineral-based pharmacologic agents, has announced positive [...]

    October 1, 2025
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Global health,Medical devices,Pharmaceuticals and therapeutics,Regulatory Affairs

    Hansa Biopharma reports statistically significant improvement in kidney function, supporting planned BLA submission

    Hansa Biopharma AB has announced positive topline results from the [...]

    September 26, 2025
  • Cell & Gene Therapy,Chronic diseases,Clinical Development,Pharmaceuticals and therapeutics

    Persista Bio wins NIH funding to advance O2Line cell therapy

    Persista Bio has been awarded two grants from the US [...]

    September 24, 2025
  • Chronic diseases,Clinical Trials,Pharmaceuticals and therapeutics,Regulatory Affairs

    Tezspire recommended for EU approval for chronic rhinosinusitis with nasal polyps

    AstraZeneca and Amgen’s Tezspire (tezepelumab) has received a positive opinion [...]

    September 23, 2025
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Global health,Market Access & Commercialization,Medical devices,Patient Centricity,Pharmaceuticals and therapeutics,Regulatory Affairs

    Terumo BCT expands access to rare disease therapies across Latin America

    Terumo Blood and Cell Technologies has announced regulatory approvals for [...]

    September 22, 2025
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Patient Centricity,Pharmaceuticals and therapeutics,Real world evidence,Regulatory Affairs

    Saphnelo self-administration Phase 3 trial meets primary endpoint in systemic lupus erythematosus

    AstraZeneca has reported positive interim results from the Phase 3 [...]

    September 22, 2025
  • Chronic diseases,Digital Health,Medical devices,Patient Centricity,Pharmaceuticals and therapeutics,Technology and platforms

    electronRx to launch app for remote respiratory disease management

    electronRx will launch its pDx app at the HLTH 2025 [...]

    October 2, 2025
  • Chronic diseases,Clinical Trials,Medical devices,Patient Centricity,Pharmaceuticals and therapeutics,Research & Development

    BIG D-FOOT trial results on STIMULAN to be presented at EBJIS 2025

    Biocomposites will present new clinical data from the BIG D-FOOT [...]

    September 17, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • HeliosX strengthens leadership team to drive global growth and brand innovation
    Categories: Digital Health, Global health, Market Access & Commercialization, Movers & Shakers, Patient Centricity, Pharmaceuticals and therapeutics, Technology and platforms
  • SeaBeLife secures €2 million to advance dual-targeted therapies for dry AMD and severe acute hepatitis
    Categories: Biotech, Clinical Development, Clinical Trials, Drug Development, Global health, Partnerships & Funding, Rare Diseases, Research & Development
  • Amorphical reports positive interim results from ongoing Crohn’s disease trial
    Categories: Chronic diseases, Clinical Development, Clinical studies, Clinical Trials, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top